AbstractBackgroundFetal and neonatal alloimmune thrombocytopenia (FNAIT) is a condition during pregnancy, which can lead to thrombocytopenia and a bleeding tendency with intracranial hemorrhage (ICH) being the most concerning complication in the fetus or neonate. An incompatibility between human platelet antigen (HPA)‐1a accounts for the majority of FNAIT cases. Binding of HPA‐1a‐specific alloantibodies to their target on fetal platelets and endothelial cells can induce apoptosis of megakaryocytes, disrupt platelet function, and impair angiogenesis. Currently, there is no screening program to identify pregnancies at risk for severe disease. A better understanding of HPA‐1a‐specific antibody heterogeneity in FNAIT could aid in identifying pathogenic antibody properties linked to severe disease.Study Design and MethodsThis study aimed to isolate HPA‐1a‐specific B‐cells from an HPA‐1a‐alloimmunized pregnant woman. Using fluorescently labeled HPA‐1a‐positive platelets, single B‐cells were sorted and cultured for 10 days to stimulate antibody production. Subsequently, supernatants were tested for the presence of antibodies by enzyme‐linked immunosorbent assay and their reactivity towards HPA‐1a‐positive platelets. Amplification and sequencing of variable regions allowed the generation of monoclonal antibodies using a HEK‐Freestyle‐based expression system.ResultsThree platelet‐specific B‐cells were obtained and cloned of which two were specific for HPA‐1a, named D‐ and M‐204, while the third was specific for HLA class I, which was named L‐204.DiscussionThis study outlined an effective method for the isolation of HPA‐1a‐specific B‐cells and the generation of monoclonal antibodies. Further characterization of these antibodies holds promise for better understanding the pathogenic nature of alloantibodies in FNAIT.